NFKB1 and triple-A syndrome: These results suggest that miR-9-5p corrects the NF-κB–Nrf2 imbalance caused by AAA by targeting and inhibiting NF-κB, thereby increasing antioxidant capacity and reducing the release of inflammatory factors.